

Corporate Action Notice



March 15, 2021

Reverse Stock Split and Ratio Change & Name Change-REVISED

Anchiano Therapeutics Ltd.

ADS CUSIP: 03280X102

ADS ISIN: US3280X1028

ADS Ticker Symbol: ANCN

Ratio (ADS: Underlying Shares): 1: 5

BNY MELLON HAS ESTABLISHED THE FOLLOWING DATES FOR THIS CORPORATE ACTION:

ADS Effective Date:	March 17, 2021
Exchange Rate:	1 New DSs for 16 Old DSs
Old CUSIP:	03280X102
New CUSIP:	16385C104
New Ratio:	1:20
Cancellation Fee:	\$0.046875

Please be advised that Anchiano Therapeutics Ltd ("Anchiano Therapeutics") has announced a share consolidation of one (1) for four (4) existing shares on its ordinary shares in the local market effective March 16, 2021. BNY Mellon at the direction of Anchiano Therapeutics Ltd will change the ratio on the Anchiano Therapeutics Ltd. American Depositary Receipt ("ADR") program.

The ratio will change from one (1) American Depositary share ("ADS") representing five (5) ordinary shares to one (1) ADS representing twenty (20) ordinary shares. The ratio change will occur simultaneously with a one (1) for sixteen (16) reverse stock split on the ADRs.

Please also be advised that Anchiano Therapeutics Ltd announce a name change to **Chemomab Therapeutics Ltd. ("Chemomab Therapeutics")**.

Effective March 17, 2021 ADR holders of Anchiano Therapeutics Ltd. will be required on a mandatory basis to surrender their old ADRs to BNY Mellon for cancellation and exchange at a rate of one (1) Chemomab Therapeutics ADSs (CUSIP 16385C104) for every sixteen (16) Anchiano Therapeutics ADSs (CUSIP 03280X102) surrendered. Holders of ADSs in the Direct Registration System or in brokerage accounts will have their ADSs automatically exchanged and need not take any action. No fraction of an ADS will be issued. BNY Mellon will attempt to sell any fractions and distribute the cash proceeds to holders. A cancellation fee of \$0.046875 per Old ADS surrendered will be charged.

BNY Mellon's books will be closed for all issuance and cancellation transactions on CUSIP# 03280X102 as of the close of business March 15, 2021. BNY Mellon expects to reopen the books on CUSIP# 16385C104 on March 17, 2021.

To learn more about Depositary Receipts please contact DRBrokerSolutions@bnymellon.com or visit our website at adrbnymellon.com.

PLEASE SEE INVESTOR DISCLOSURE ON LAST PAGE.

Investor Disclosure

This notice and the information and data provided herein are provided for general informational purposes only. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data. BNY Mellon does not undertake any obligation to update or amend this notice or any information or data, and may change, update or amend this notice or any information or data at any time without prior notice.

BNY Mellon provides no advice, recommendation or endorsement with respect to any company or securities. No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such. We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon this notice or any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

BNY Mellon collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued. From time to time, BNY Mellon may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program. BNY Mellon may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor. BNY Mellon may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. BNY Mellon may execute DR foreign currency transactions itself or through its affiliates; in such cases it acts as principal counterparty and not as agent, advisor, broker or fiduciary. BNY Mellon has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY Mellon earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account. The methodology used by BNY Mellon to determine DR conversion rates is available to registered Owners upon request or at https://www.adrbnymellon.com/us/en/news-and-publications/dr-issuers/asset_upload_file49220_197380.pdf.

This notice or any excerpt of this notice may not be copied or reproduced without the prior express written consent of BNY Mellon.

BNY Mellon is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle. BNY Mellon is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

BNY Mellon's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY Mellon.

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY MELLON AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.